Wockhardt has received an ‘import alert’ from UK medicines and Healthcare Products Regulatory Agency (MHRA) for export-oriented plant at Waluj in Aurangabad. Import alert was made due to certain deviations from its quality manufacturing norms at the company’s plant at Waluj. Earlier in May, the company received an ‘import alert’ from USFDA on one of its manufacturing unit located in Waluj near Aurangabad.
The impact of the import alert on the revenues is estimated to be in the range of $100 million on an annualised basis. The company is planning to shift production elsewhere and restore manufacturing within six to nine months.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1861.70 |
Dr. Reddys Lab | 1389.35 |
Cipla | 1506.15 |
Lupin | 2228.00 |
Zydus Lifesciences | 972.70 |
View more.. |